Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease
Olivia Wagemann,Haiyan Liu,Guoqiao Wang,Xinyu Shi,Tobias Bittner,Marzia A. Scelsi,Martin R. Farlow,David B. Clifford,Charlene Supnet-Bell,Anna M. Santacruz,Andrew J. Aschenbrenner,Jason J. Hassenstab,Tammie L. S. Benzinger,Brian A. Gordon,Kelley A. Coalier,Carlos Cruchaga,Laura Ibanez,Richard J. Perrin,Chengjie Xiong,Yan Li,John C. Morris,James J. Lah,Sarah B. Berman,Erik D. Roberson,Christopher H. van Dyck,Douglas Galasko,Serge Gauthier,Ging-Yuek R. Hsiung,William S. Brooks,Jérémie Pariente,Catherine J. Mummery,Gregory S. Day,John M. Ringman,Patricio Chrem Mendez,Peter St. George-Hyslop,Nick C. Fox,Kazushi Suzuki,Hamid R. Okhravi,Jasmeer Chhatwal,Johannes Levin,Mathias Jucker,John R. Sims,Karen C. Holdridge,Nicholas K. Proctor,Roy Yaari,Scott W. Andersen,Michele Mancini,Jorge Llibre-Guerra,Randall J. Bateman,Eric McDade,Alisha J. Daniels,Laura Courtney,Xiong Xu,Ruijin Lu,Emily Gremminger,Erin Franklin,Laura Ibanez,Gina Jerome,Elizabeth Herries,Jennifer Stauber,Bryce Baker,Matthew Minton,Alison M. Goate,Alan E. Renton,Danielle M. Picarello,Russ Hornbeck,Allison Chen,Charles Chen,Shaney Flores,Nelly Joseph-Mathurin,Steve Jarman,Kelley Jackson,Sarah Keefe,Deborah Koudelis,Parinaz Massoumzadeh,Austin McCullough,Nicole McKay,Joyce Nicklaus,Christine Pulizos,Qing Wang,Edita Sabaredzovic,Hunter Smith,Jalen Scott,Ashlee Simmons,Jacqueline Rizzo,Jennifer Smith,Sarah Stout,Celeste M. Karch,Jacob Marsh,David M. Holtzman,Nicolas Barthelemy,Jinbin Xu,James M. Noble,Snezana Ikonomovic,Neelesh K. Nadkarni,Neill R. Graff-Radford,Takeshi Ikeuchi,Kensaku Kasuga,Yoshiki Niimi,Edward D. Huey,Stephen Salloway,Peter R. Schofield,Jacob A. Bechara,Ralph Martins,David M. Cash,Natalie S. Ryan,Christoph Laske,Anna Hofmann,Elke Kuder-Buletta,Susanne Graber-Sultan,Ulrike Obermueller,Yvonne Roedenbeck,Jonathan Vӧglein,Jae-Hong Lee,Jee Hoon Roh,Raquel Sanchez-Valle,Pedro Rosa-Neto,Ricardo F. Allegri,Ezequiel Surace,Silvia Vazquez,Francisco Lopera,Yudy Milena Leon,Laura Ramirez,David Aguillon,Allan I. Levey,Erik C.B Johnson,Nicholas T. Seyfried,Anne M. Fagan,Hiroshi Mori,Colin Masters,
DOI: https://doi.org/10.1001/jamaneurol.2024.0991
IF: 29.907
2024-04-29
JAMA Neurology
Abstract:Importance Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited Alzheimer disease (DIAD). Objective To investigate longitudinal biomarker changes of synaptic dysfunction, neuroinflammation, and neurodegeneration in individuals with DIAD who are receiving antiamyloid treatment. Design, Setting, and Participants From 2012 to 2019, the Dominantly Inherited Alzheimer Network Trial Unit (DIAN-TU-001) study, a double-blind, placebo-controlled, randomized clinical trial, investigated gantenerumab and solanezumab in DIAD. Carriers of gene variants were assigned 3:1 to either drug or placebo. The present analysis was conducted from April to June 2023. DIAN-TU-001 spans 25 study sites in 7 countries. Biofluids and neuroimaging from carriers of DIAD gene variants in the gantenerumab, solanezumab, and placebo groups were analyzed. Interventions In 2016, initial dosing of gantenerumab, 225 mg (subcutaneously every 4 weeks) was increased every 8 weeks up to 1200 mg. In 2017, initial dosing of solanezumab, 400 mg (intravenously every 4 weeks) was increased up to 1600 mg every 4 weeks. Main Outcomes and Measures Longitudinal changes in CSF levels of neurogranin, soluble triggering receptor expressed on myeloid cells 2 (sTREM2), chitinase 3–like 1 protein (YKL-40), glial fibrillary acidic protein (GFAP), neurofilament light protein (NfL), and plasma levels of GFAP and NfL. Results Of 236 eligible participants screened, 43 were excluded. A total of 142 participants (mean [SD] age, 44 [10] years; 72 female [51%]) were included in the study (gantenerumab, 52 [37%]; solanezumab, 50 [35%]; placebo, 40 [28%]). Relative to placebo, gantenerumab significantly reduced CSF neurogranin level at year 4 (mean [SD] β = −242.43 [48.04] pg/mL; P < .001); reduced plasma GFAP level at year 1 (mean [SD] β = −0.02 [0.01] ng/mL; P = .02), year 2 (mean [SD] β = −0.03 [0.01] ng/mL; P = .002), and year 4 (mean [SD] β = −0.06 [0.02] ng/mL; P < .001); and increased CSF sTREM2 level at year 2 (mean [SD] β = 1.12 [0.43] ng/mL; P = .01) and year 4 (mean [SD] β = 1.06 [0.52] ng/mL; P = .04). Solanezumab significantly increased CSF NfL (log) at year 4 (mean [SD] β = 0.14 [0.06]; P = .02). Correlation analysis for rates of change found stronger correlations between CSF markers and fluid markers with Pittsburgh compound B positron emission tomography for solanezumab and placebo. Conclusions and Relevance This randomized clinical trial supports the importance of fibrillar amyloid reduction in multiple AD-related processes of neuroinflammation and neurodegeneration in CSF and plasma in DIAD. Additional studies of antiaggregated amyloid therapies in sporadic AD and DIAD are needed to determine the utility of nonamyloid biomarkers in determining disease modification. Trial Registration ClinicalTrials.gov Identifier: NCT04623242
clinical neurology